Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: Pros and cons?

Elisa Gremese, Gianfranco Ferraccioli, Barbara Tolusso

Risultato della ricerca: Contributo in rivistaArticolo in rivista

3 Citazioni (Scopus)

Abstract

The CERERRA database provides evidence that low-dose rituximab performs as well as the conventional dose in the real world, thus highlighting the possible pharmacoeconomic impact. In clinical trials, it has been shown that rituximab 500 mg twice, performs as well as 1 g twice, 2 weeks apart, in terms of the American College of Rheumatology (ACR)20 and ACR50, but not the ACR70. The choice should always be made after considering that the IMAGE trial has demonstrated similar radiographic progression after the first 6 months, but with less control, with low-dose rituximab in the first 6 months. A possible alternative can be hypothesized.
Lingua originaleEnglish
pagine (da-a)126-N/A
RivistaARTHRITIS RESEARCH & THERAPY
Volume18
DOI
Stato di pubblicazionePubblicato - 2016

Keywords

  • High dose
  • Immunology
  • Immunology and Allergy
  • Low dose
  • Peripheral B cell depletion
  • Rheumatology
  • Rituximab
  • Synovial tissue B cell depletion

Fingerprint Entra nei temi di ricerca di 'Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: Pros and cons?'. Insieme formano una fingerprint unica.

Cita questo